Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after PD1 inhibition with nivolumab

Abstract

We were fascinated to read the observations of Bandino et al. who described two patients who developed keratoacanthomas and squamous cell carcinoma in association with bullous pemphigoid-like lesions after treatment with PD-1 inhibitors, nivolumab or pembrolizumab, in a recent issue of the Journal. Herein we report two patients with no prior history of skin cancer who developed eruptive keratoacanthomas in the setting of lichenoid skin toxicity after starting nivolumab.

This article is protected by copyright. All rights reserved.

http://ift.tt/2vyg5Fw